论文部分内容阅读
目的观察曲美他嗉对慢性充血性心力衰竭(CHF)患者的临床疗效。方法52例符合要求的慢性充血性心力衰竭患者,随机分为治疗组和对照组,两组均给予常规抗心力衰竭治疗,治疗组给予曲美他嗉20mg,3次/d。观察治疗24周后的心功能分级,左室收缩末容积指数(LVESVI)、左室舒张末容积指数(LVEDVI)和左室射血分数(LVEF)。结果治疗组治疗后的左心室功能改善临床总有效率为88.5%,较对照组(69.2%)显著提高(p<0.05),治疗后与治疗前相比LVESVI、LVEDVI和LVEF均有显著改善(p<0.01),两组间比较曲美他嗉组较对照组疗效更为显著(p<0.05)。结论CHF患者在常规治疗基础上加用曲美他嗉治疗,可进一步改善患者的心功能。
Objective To observe the clinical efficacy of trimetazidine in patients with chronic congestive heart failure (CHF). Methods Fifty-two patients with chronic congestive heart failure were randomly divided into treatment group and control group. Both groups were given conventional anti-heart failure treatment. The treatment group was given trimetazidine 20 mg three times daily. Cardiac function scores, LVESSVI, LVEDVI and LVEF were observed 24 weeks after treatment. Results After treatment, the total effective rate of improvement of left ventricular function in treatment group was 88.5%, which was significantly higher than that in control group (69.2%) (p <0.05), LVESVI, LVEDVI and LVEF were significantly improved after treatment p <0.01). The effect of trimetazidine on the two groups was more significant than that of the control group (p <0.05). Conclusions CHF patients with trimetazidine combined with conventional therapy can further improve their cardiac function.